A recent phase 2 trial investigated the triple biased GLP-1/GIP/GCC receptors agonist retatrutide (LY3437943) in 338 patients with a mean age of 48 years and BMI of 37.3 kg/m 2 without diabetes (prediabetes in 36% participants) showing BW and WC reduction ranging from 8.7% to 24.2% and 6.5 cm to 19.6 cm in the 1 mg and 12 mg dose groups, respectively, at 48 weeks 41
This makes it an ideal candidate for research into obesity, type 2 diabetes, and metabolic syndrome
There is also further ongoing research to understand the mechanisms of GIP agonism versus antagonism to decide on the optimal weight loss and antihyperglycemic approach
The coordinated increase in fat mobilization and oxidation creates a metabolic environment optimized for fat loss while sparing lean tissue
These conditions often go hand in hand, fueling complications such as cardiovascular disease, fatty liver disease, and metabolic syndrome
By considering all prescriptions within a defined 100-day window around BMI events, this approach offers a broader view of prescribing trends among adolescents with obesity, allowing us to assess ongoing treatment patterns rather than just initial prescriptions
